Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option by Castagnari, Aldo
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Proceedings
Open Access Proceedings
Conclusions of the expert panel: importance of erlotinib as a 
second-line therapeutic option
Aldo Castagnari
Address: Centro Integral de Oncología. Leandro N. Alem 460 (1832) Lomas de Zamora, Provincia de Buenos Aires, Argentina
Email: Aldo Castagnari - aldoecastagnari@speedy.com.ar
Abstract
During the Experts Meeting on Lung Cancer, participants emphasized the usefulness of erlotinib as
second-line therapy for lung cancer. They noted that, although there are no comparative studies,
erlotinib could be as effective as docetaxel and pemetrexed in second-line therapy. Regarding the
toxicity profile of each of these drugs – one of the key issues considered in the meeting – specialists
pointed out how important it is to clearly identify existing differences in this issue. Each drug has
different degrees of toxicity, and this information is crucial at the time of choosing the therapeutic
regimen. Erlotinib treatment could be an effective option for second-line therapy.
Effectiveness: erlotinib compared with 
docetaxel and pemetrexed
In this respect, the expert panel cannot give a conclusive
answer because up to now no direct phase III comparative
studies have been carried out on these drugs. By analyzing
current evidence, they can indirectly infer that, for second-
line treatment, erlotinib seems as effective as docetaxel in
terms of survival. In spite of the lack of comparative expe-
riences, pemetrexed would be at least as effective as
docetaxel, and erlotinib might be as effective as the other
two drugs.
In the first-line setting, cytotoxic chemotherapy is consid-
ered to be superior to erlotinib as regards overall patient
population [1-3]; and in third-line therapy, erlotinib is
the only effective treatment. However, in the second-line
setting, a thorough selection of patients is required [4]. If
it is concluded that these drugs are similar regarding effi-
cacy, the decision should take into account individual
aspects of each case. For instance, in a smoker without
comorbidities, chemotherapy will probably be preferable.
In contrast, in a female with adenocarcinoma and no
smoking history, treatment with erlotinib seems to be the
most suitable option, though according to the study
review, erlotinib has been seen to be beneficial for all sub-
groups [5,6]. This clearly shows that on no account are
these treatments competing, but that each case's particular
aspects must be contemplated. For example, erlotinib
could be considered in elderly patients [7] (i.e., older than
70) and in those patients with suboptimal performance
status or comorbid conditions.
Toxicity/safety of drugs indicated for second-line 
treatment of NSCLC
Experts have stressed the fact that by administering
docetaxel and pemetrexed, hematologic and hepatic toxic-
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ity prevail, whereas with erlotinib the main toxicities are
adverse skin and, to a lesser extent, gastrointestinal events.
In fact, docetaxel and pemetrexed are associated with
febrile neutropenia, while this complication has not been
reported with erlotinib.
One of the reasons to discontinue erlotinib is its biologi-
cal effect, seen in the occurrence of treatment-related rash.
Patients with severe conditions who see their appearance
seriously affected often refuse to continue taking medica-
tion. Faced with this situation, physicians should learn
how to deal with skin effects and be well aware of toxicity
grade; in case of toxicity grade 3, the dose should be
reduced or the administration scheme modified, includ-
ing treatment discontinuity for less than two weeks and
then resumption of usual dose.
Evidence shows that second-line therapeutic options
seem to be roughly comparable as regards response [8,9].
In order to choose the most convenient therapy, experts
should evaluate the conditions in each case together with
the patient, who should be well informed as to the toxicity
profile of each drug. To stress the fact that the toxicity of
each therapeutic option is different is essential.
Data seem to suggest that the safety profile of erlotinib is
more favourable than that of commonly used second-line
drugs. While in some cases the administration of erlotinib
produces biological skin effects, these can be controlled
by an adequate intervention on the part of the physician,
who may adjust the dose or, in extreme cases, discontinue
it temporarily.
A direct relationship between the skin effect and the ther-
apeutic response to erlotinib has been observed [10-12].
The greater the skin toxicity, the better the survival seems
to be. This may be a key observation to obtain consent
from patients who will undergo treatment with erlotinib.
It should be noted that while there are no reported cases
of death related to erlotinib treatment, death has been
reported with the use of the other drugs.
Experts have agreed on the importance of interdiscipli-
nary work in the treatment of toxic effects. Multidiscipli-
nary care allows comprehensive assistance and specific
solutions for each individual area. This is essential to help
patients experiencing serious adverse effects or effects that
have a high impact on quality of life, since most often the
resulting impairment is very hard to deal with. With erlo-
tinib therapy, if toxic skin effects occur, the assistance of
and joint work with skin specialists is recommended.
At this point, regarding the outcome of toxic skin effects,
patients who develop significant rashes do so usually in
the 2nd or 3rd week after treatment onset. Then, lesions
usually begin to disappear few weeks later.
It is important to point out that erlotinib is administered
orally and only once a day. This is a great advantage over
other therapeutic agents requiring intravenous adminis-
tration, which may have negative effects. In addition,
unlike the other currently available options, erlotinib
does not require the administration of pre-established
additional medication.
Patient selection
So far, evidence is inadequate to establish a clinical or
molecular profile for patient selection. Many of the data
come from observations in non-randomised trials. The
greatest therapeutic benefits were reported in female non-
smokers with bronchioloalveolar carcinoma.
Prevailing information about molecular profile was ini-
tially provided by clinical trials of gefitinib, where a higher
response rate was observed among female non-smokers
with adenocarcinoma. From then on, the idea has pre-
vailed that the population with these characteristics is
more likely to show a favourable response.
While certain similarities are seen with erlotinib, a great
number of patients has been shown to have a favourable
response (not necessarily a longer survival), despite their
having different characteristics. Notwithstanding, the best
clinical response in the second-line setting is apparently
achieved in female non-smokers with adenocarcinoma.
At present, there is no evidence to select the candidate
patient for erlotinib through the clinical or molecular pro-
file, though there are patient subgroups that benefit more
than others [13].
Relationship between toxic skin effects and 
biological effect of erlotinib
The BR.21 [6] trial shows that the most important toxic
effects of erlotinib are firstly related to skin rash and, sec-
ondly, to diarrhea. Regarding response prediction, litera-
ture on this subject points out that skin adverse effects
would be a surrogate marker of the biological-therapeutic
effect. Skin toxicity curves and their corresponding
responses have been published: the higher the skin toxic-
ity, the higher the response. Specifically, reports show that
patients with grade 3 and 4 rash had an 80% response. In
contrast, individuals with grade 2 toxicity showed a much
lower response (12%). In this respect, all experts have
agreed: rash may be an objective marker of response to
erlotinib treatment [10-12].BMC Proceedings 2008, 2(Suppl 2):S4 http://www.biomedcentral.com/1753-6561/2/S2/S4
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Conventional chemotherapy vs. targeted 
therapies (in the first-, second- and, if necessary, 
third-line setting)
Unlike other drugs, erlotinib has shown clinical activity in
all therapeutic lines. Therefore, it would be the physician's
decision to administer it, based on each patient's charac-
teristics – and clinical considerations as well –, for exam-
ple, taking into account the drug's availability. However,
erlotinib is not currently accepted as a first-line treatment.
In third-line treatment, there are no doubts regarding the
indication of erlotinib; in second-line, according to the
opinions presented, there is none either. However, for the
time being, scientific evidence is not enough for first-line
treatment, and future results have to be awaited.
Special cases may arise, such as patients who are not can-
didates for or refuse chemotherapy and who are pre-
scribed erlotinib as first treatment option. The use of
erlotinib as first-line treatment – with some exceptions –
will then depend on the results of ongoing studies. It
should be noted that in previous phase III randomized tri-
als, combination cytotoxic chemotherapy with erlotinib
in the first-line setting was shown to be no more benefi-
cial than combination chemotherapy alone. [2,14,15].
Differences between HER1/EGFR inhibitors: 
erlotinib and gefitinib
There are no studies comparing these two drugs. Evidence
suggests that erlotinib is better than gefitinib: the former
had significant impact on survival rate, while the latter did
not.
Anecdotal observations suggest that the grade of skin tox-
icity is much higher for erlotinib than for gefitinib. With
gefitinib, grade 3 and 4 toxicity is generally low. For
adverse gastrointestinal and skin events, similar data were
reported; i.e., the incidence and grade of rash and diarrhea
are higher with erlotinib than with gefitinib. This fact may
explain the different therapeutic results obtained.
The pharmacokinetic explanation accounting for the dif-
ference between gefitinib and erlotinib lies in the fact that
in the ISEL trial gefitinib was not dosed close to its maxi-
mum tolerated dose (MTD), a fact which is also related to
the grade of adverse effects reported. If the optimum dose
is lower than the MTD, adverse effects will then be lower
since plasma concentrations are not the ideal ones and
effectiveness is also lower. Whether higher doses of gefit-
inib are more effective, yet also more toxic, should be
determined. Conversely, erlotinib is administered at an
optimum dose that is very close to the MTD; thus, biolog-
ical side effects are higher. Clinical evidence shows that
erlotinib is more effective than gefitinib regarding impact
on survival, with respect to placebo [16].
Influence of pharmacokinetic (PK)-
pharmacodynamic (PD) relationship of erlotinib 
on response and safety
There are a number of well-known recommendations
regarding this subject, such as avoiding the intake of some
citrus fruits and the combination of treatment with anti-
coagulants and antifungals, among other contraindicated
drugs.
There are no practical recommendations regarding phar-
macokinetics, except that it is important for the patient to
take the medication under fasting conditions so as to pre-
serve ideal plasma concentrations, and preferably not to
smoke during treatment.
Cost-effectiveness: erlotinib compared with 
other therapies
Overall, cost-effectiveness comparisons with the other
two options for second-line treatment show higher bene-
fits for erlotinib in international studies applied to other
countries.
In Latin America, two studies analyzing cost-effectiveness
took into account not only medication and health service
costs but also the cost of the complications that may arise
from each therapy administration, mainly chemotherapy-
related febrile neutropenia and erlotinib-related rash and
diarrhea [17]. According to research carried out with
docetaxel and pemetrexed, which took into account ther-
apy overall costs, including additional medication (e.g.,
colony-stimulating factor, antibiotics) and mainly hospi-
talization costs, the cost of docetaxel was higher as com-
pared with that of pemetrexed.
There is no knowledge of cost-effectiveness analyses of
erlotinib carried out by local health institutions. However,
an independent consulting firm performed a local analy-
sis focused on women with adenocarcinoma, and com-
pared erlotinib's cost-effectiveness with that of docetaxel,
showing a cost-effectiveness advantage for erlotinib. This
analysis took into account response to treatment and
patient survival based on local data from the TRUST trial,
and official costs of hospital resources and supplies.
From these data, they might say that cost-effectiveness of
erlotinib is comparable to the rest of therapies or, at least,
is not higher. According to available data from cost-effec-
tiveness analyses worldwide, docetaxel and pemetrexed
are equivalent to erlotinib. Further specific local studies
for each health institution will be required.
Timely referral of patients with lung cancer
The education general practitioners receive on oncology
questions is most important. Information should be
spread to all the medical community that there are effec-Publish with BioMed Central    and   every 
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tive therapies for lung cancer, not only aimed at survival
but also at quality of life, and that there are increasing
options for first-, second- and third-line treatment.
Lung cancer is a disease that requires a multidisciplinary,
multiinstitutional approach. The intervention of different
secondary and tertiary care institutions is needed, as well
as the implementation of better local epidemiologic sys-
tems. Lung cancer presentation and histopathology are
varied, thus requiring joint work to improve patients'
referral so that they may receive the most appropriate
treatment.
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